0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD59

CD59

Brief Information

Name:CD59 glycoprotein
Target Synonym:CD59 Antigens,Membrane attack complex inhibition factor,Membrane inhibitor of reactive lysis,MEM43 antigen,HRF-20,MIRL,20 kDa homologous restriction factor,MAC-inhibitory protein,MACIF,Protectin,MAC-IP,1F5 antigen,P18-20,CD59 Molecule, Complement Regulato
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CD9-H82E3 Human Biotinylated Human CD59 Protein, His,Avitag™
CD9-H82E3-structure
CD9-H82E3-sds
CD9-H52H9 Human Human CD59 Protein, His Tag
CD9-H52H9-structure
CD9-H52H9-sds

Synonym Name

CD59,16.3A5,1F5,EJ16,EJ30,EL32,FLJ38134,FLJ92039,G344,HRF20,MAC-IP,MACIF,MEM43,MGC2354,MIC11,MIN1,MIN2,MIN3,MIRL,MSK21,p18-20,Protectin

Background

CD59, also known as membrane attack complex inhibition factor (MACIF), Protectin, 1F5 antigen, HRF-20 and MIRL. CD59 has been identified as a glycosylphosphatidylinositol-anchored membrane protein that acts as an inhibitor of the formation of the membrane attack complex to regulate complement activation. Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
HMR-59 HMR-59 Phase 1 Clinical Tufts University Geographic Atrophy; Macular Degeneration Details

This web search service is supported by Google Inc.

totop